Skip to main content
. Author manuscript; available in PMC: 2022 Jan 14.
Published in final edited form as: Cell Rep. 2022 Jan 11;38(2):110216. doi: 10.1016/j.celrep.2021.110216

Figure 5. ATRX-deficient human glioma cells demonstrate selective radio-sensitization with ATM inhibition.

Figure 5.

(A) Illustration of mechanism by which ATR and ATM proteins enforce cell cycle checkpoints. (B) Enhancement ratio after 4 Gy IR (clonogenic assay) performed on SJGBM2 cells against ATR (purple) and ATM (green) inhibitors. (C) In vitro proliferation assay plot of various radiation doses of ATM inhibitor AZD0156 for KNS42 and SJGBM2 (above) and ATRX isogenic U251 cells (below). (D) Plot of tumor cell confluence over time for U251 isogenic ATRXKO cell cultures treated with increasing concentrations of AZD0156 at 1 Gy XRT. (E) Immunoblots for ATR (purple) and ATM pathway (green) at baseline, by IR with DMSO and IR with 1 uM AZD0156 in U251 isogenic ATRXKO cells. [Mean ± SEM for triplicate experiments are shown. **p≤ 0.01 using Welch’s t-test] For additional data, see also Figures S5 and S6.